Pharma stocks drop on Trump drug price reform proposals

Trump's proposals to allow Medicare price negotiations and cap out-of-pocket costs will likely pressure pharmaceutical stock valuations, particularly for high-margin drugmakers. Investors may sell shares in companies like Pfizer and Merck in anticipation of lower revenue.

Implied probability (Yes)

75%